Compare Gilead Sciences, Inc. (GILD) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs ResMed Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.67 (market cap $163.51B), while ResMed Inc. trades at $201.99 (market cap $28.80B). The key difference: Gilead Sciences, Inc. is far larger — about 5.7× ResMed Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | RMD | |
|---|---|---|
Market Cap | $163.51B | $28.80B |
Sector | Health | Health |
52-Week High | $155.80 | $293.73 |
52-Week Low | $108.22 | $182.82 |
Enterprise Value | $178.05B | $27.99B |
Dividend Yield | 2.49% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
ResMed (RMD) trades at $201.44, up 4.37% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 27.44% net margins and consistent revenue growth from $3.6B in 2022 to $5.15B in 2025. Recent strategic moves include divesting MatrixCare for $490M to sharpen focus on core sleep and respiratory care markets.
RMD presents a compelling growth story with analyst consensus pointing to 28% upside potential to $245.88. However, technical weakness and competitive pressures in the medical device space warrant caution. The company's strong cash flow generation and dividend payments provide shareholder value, but investors should monitor execution risks from the business portfolio restructuring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
